Acute visual loss following dapsone-induced methemoglobinemia and hemolysis. (June 2015)

• Record Type: Journal Article
• Authors: Hanuschk, Delphine; Kozyreff, Alexandra; Tafzi, Naima; Tennstedt, Dominique; Hantson, Philippe; Saint-Marcoux, Franck
• Is Part Of: Clinical toxicology. Volume 53:Number 5(2015)
• Page Start: 489
• Page End: 492
• Publication Date: 2015-06
• Subjects: Dapsone -- Overdose -- Methemoglobin -- Hemolytic anemia -- Alpha-Thalassemia -- Hemoglobin S trait -- Retinal ischemia; Toxicology -- Periodicals; Toxicological emergencies -- Periodicals; 615.9
• DOI: 10.3109/15563650.2015.1033631
• Languages: English
• ISSNs: 1556-3650

Abstract

Abstract: Objective. While methemoglobinemia is a possible complication of chronic dapsone therapy or of acute overdose, serious adverse manifestations related to methemoglobin formation remain rare. We present an unusual case with severe ischemic retinal injury. Case report. A 30-year-old African woman presented with a sudden decrease of visual acuity secondary to retinal ischemia. She was chronically treated with dapsone (50 mg/day) for a dermatologic disease and denied any drug overdose. However, the determination of serum dapsone level on admission revealed a largely supratherapeutic concentration (20, 044 μg/ml compared with 1–3.5 ± 0.5 μg/ml for therapeutic levels). The methemoglobin level at admission was 32% (sulfhemoglobin 1.2%), with hemoglobin level, 7.4 g/dl, schistocytes count, 2–5%, lactate dehydrogenase level, 580 IU/l, and haptoglobin level, < 10 mg/dl. The patient had both alpha-thalassemia and sickle cell trait. She was treated with methylene blue, vitamin C, and exchange transfusion. There was no improvement in visual symptoms over time. Conclusions. In a patient with supratherapeutic serum levels of dapsone, the severity of visual injury was associated with dapsone-induced methemoglobinemia and hemolysis, and perhaps also with some hematologic predisposing factors.